[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tarian Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100628133","phase-2-tar-0520-gel-in-hand-and-foot-syndrome-100628133",false,"NCT07457671","TAR-0520 Gel in Hand and Foot Syndrome","A Phase 2a Exploratory Study of TAR-0520 Gel in Prevention of Hand and Foot Syndrome","TARIAN008","Inclusion Criteria:\n\n* Medical diagnosis of breast or colorectal cancer planned to be treated with capecitabine\n* at a dose \\> 1000mg\u002Fm² twice daily every 2 out of 3 weeks as single agent chemotherapy\n* Patients with life expectancy graeter than 12 weeks\n\nExclusion Criteria:\n\n* Patient with medical history of capecitabine treatment\n* patient with pre-existing neuropathy confounding assessement of HFS\n* Patient with Raynaud's syndrome or other vascular peripheral disorders\n* Patient with dermatological lesions on hands or foot","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Hand and Foot Syndrome (HFS) is a weii-established and frequent cutaneous adverse event of capecitabine used in the treatment of different cancers.HFS is charectirized by a variety of symptoms ranging from mild discomfort to a painful sensation of palms and sols that could limit functionality and hamper patients on their daily activities.\n\nThe aim of this study is to explore the TAR-0520 gel safety and preventive efficacy of HFS in patients with colorectal and breast cancer patients treated with capecitabine.\n\nIs the product well tolerated locally and systemically ? Is the product reducing frequency and severity of HFS ? Is product improving Quality of Life (QoL) of treated patients ? Each patient will receive the active TAR-0520 gel and they will apply it to both hands,twice daily. Applications will be done 1 hour before each morning and evening capecitabine oral intake.\n\nFeet will be not treated and will serve as controls. In total , this study will follow patients during 4 capecitabine Cycles (each Cycle=21 days) for a total of 12 weeks.\n\nClinical evaluations will take place at Day1 of each Cycle and will be conducted separetaly on hands and feet.",[27],"Hand and Foot Syndrome",[27,29],"Prevention of Hand and Foot Syndrome","NOT_YET_RECRUITING","2026-03-03",{"date":33,"type":34},"2026-03-09","ACTUAL",{"date":36,"type":21},"2026-03",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"Tarian Pharma","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100599305","phase-2-safety-and-efficacy-study-of-tar-0520-gel-in-prevention-of-taxane-induced-peripheral-neuropathy-100599305","NCT07082764","Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy","A Phase 2a Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy","TARIAN 014","Inclusion Criteria:\n\n* Male or female, who is at least 18 years of age or older\n* Patients with clinical diagnosis of breast cancer\n* Patients planned to be treated with paclitaxel or docetaxel\n* Patients who can understand and sign the Informed Consent Form\n* Patients who can apply the study gel by himself \u002Fherself or has a giver that can apply the product.\n* Female patients of childbearing potential who agree to use a highly effective method of contraception throughout the study\n\nExclusion Criteria:\n\n* Patient already treated with taxanes or other chemotherapies known to induce neuropathies\n* Patient with previously diagnosed peripheral neuropathy\n* Patient with concomitant therapies known to induce neuropathies\n* Patient treated for neuropathic pain\n* Patient with comorbid factors known to induce neuropathies (such as Diabetes, Alcoholism, HIV, Peripheral vascular disease, Vitamin B deficiencies)\n* Patient currently receiving monoamine oxidase (MAO) inhibitors therapy or patients on antidepressants which affect noradrenergic transmission e.g. tricyclic antidepressants and mianserin (as mentioned in the current topical brimonidine labeling of approved products).\n* Patient who will not be able to follow the protocol for physical or psychological reasons\n* Patient with history of skin disorders, significant skin disease, irritated skin or open wounds within the same body areas planned for the IMP application.\n* Known or suspected allergies or sensitivities to any components of any of the study drugs (see Investigator's Brochure\u002FProduct label)\n* Female who is pregnant or lactating\n* Female who intends to conceive a child during the clinical trial",{"count":52,"type":21},30,[24],"Taxane -induced peripheral neuropthy (TIPN) and nail toxicites are frequent side effects of taxane therapy in breast cancer patients.. TIPN involves the hands and the feet ,its symptoms comprise numbness,tingling,altered touch sensation, impaired vibration, parasthesia and dysesthesias induced by touch, warm or cool temperatures.\n\nThis study investigate the preventive effect of TAR-0520 gel on TIPN and on nail toxicity.\n\nBreast cancer patients under taxanes therapy will apply TAR-0520 Gel to one hand and the homolateral foot including fingers and toes. Other hand and foot will be untreated and will serve as control.\n\nPatients will be followed during the 12 cycles of taxane therapy. Evaluations of TIPN will include clinical assessments by the oncologist, examination by a neurologist, patient questionnaires administered by a nurse and objective neurophysiological measures conducted by trained personnel. Evaluation of taxane nail toxicity will include a clinical grading by a nurse and a patient questionnaire.",[56],"Chemotherapy Induced Peripheral Neuropathy",[58,59],"taxane-induced peripheral neuropathy","taxane-induced nail toxicities","2025-07-16",{"date":62,"type":34},"2025-07-24",{"date":64,"type":21},"2025-09-01",{"date":66,"type":21},"2026-12-15",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":5},"100578958","phase-2-tar-0520-gel-in-egfr-inhibitor-induced-folliculitis-100578958","NCT06818058","TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis","A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.","Inclusion Criteria:\n\n* male or female, who is at least 18 years of age or older at the screening visit\n* patients with clinical diagnosis of metastatic colorectal carcinoma planned to be treated with cetuximab or panitumumab injections as part of the chemotherapy protocol\n* patients who can understand and sign the Informed Consent Form, can communicate with investigator,can understand and comply with requierements of the protocol, and can apply the study gel by himself\u002Fherself or have giver who can apply the product\n* patients with predicted life expectency of \\> 3 months\n* patients willing and able to comply with all of the time commitements and procedural requirements of the clinical trial protocol\n\nExclusion Criteria:\n\n* patients with medical history of EGFR treatment in the past 2 years\n* patients with any underlying physical ,psychological or medical condition that, in the opinion of the invstigator, would make it unlikely that the patient will comply with the protocol or complete the study protocol\n* patients with any uncotrolled or serious disease, or any medical or surgical condition,that may put the subject at significant risk (according to the investigator's judgement) if he\u002Fshe participates in the clinical trial\n* patients with history of other skin disorders (eg.atopic dermatitis,psoriasis,recurrent skin infections), or a history of illness that, in the opinion of the investigator, would confound the results of the study\n* patients with significant skin disease other than EGFRi-induced folliculits within the same body areas planned for study drug application\n* patients with a beard that would interfere with administration of the study drug and assessement of study endpoints\n* patients with active infection within the treatment area ot in other body areas that requieres initiation of systemic antibiotics\n* patients with known or suspected allergies or sensitivities to any components of the study drugs\n* female patients who are pregnant or lactating","80 Years",{"count":77,"type":21},60,[24],"A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.",[81],"EGFR Inhibitor-associated Rash",[83,84],"EGFR inhibitor-induced skin rash;","EGFR inhibitor-induced folliculitis","RECRUITING","2025-02-05",{"date":88,"type":34},"2025-02-10",{"date":90,"type":34},"2025-01-20",{"date":92,"type":21},"2026-09-30",{"name":40,"class":41},""]